Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Press Releases
  • Top Stories

Troubled Biotech Company’s Investigational Cancer Drug Gets Greenlighted By FDA

By Benzinga Neuro
January 31, 9:38 AM
This development marks a significant milestone for 23andMe, a company that has been in the spotlight for security breaches in the past.

ME

Read More
2 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • News

With Bumper $33B Sales, Novo Nordisk Forecasts Double-Digit 2024 Earnings Growth, Boosts Lower Dose Wegovy US Supplies

By Vandana Singh
January 31, 9:38 AM
Novo Nordisk reports impressive Q4 2023 sales of DKK 65.86 billion, up 43% at CER. Explore robust growth in Diabetes and Obesity care, including GLP-1 diabetes and Wegovy. CEO anticipates continued success in 2024 with sales growth of 18%-26% .

NVO

Read More
2 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Why Is European Pharma Giant Novartis Stock Trading Lower Today?

By Vandana Singh
January 31, 9:16 AM
Novartis Q4 2023 sales reach $11.42 billion, up 8%. Strong growth in key drugs, Entresto, Kisqali, Kesimpta, Cosentyx, and Pluvicto. Core operating income at $3.8 billion.

NVS

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Markets
  • News

Novo Nordisk Skyrockets To $506B Valuation Driven By ‘Miracle’ Drugs Ozempic, Wegovy

By Benzinga Neuro
January 31, 7:57 AM
The company predicts a sales growth of 18% to 26% in CER terms for the current year, driven by the soaring demand for Wegovy and Ozempic, which contain the same active ingredient.

NVO

Read More
1 minute read
  • After-Hours Center
  • Earnings
  • General
  • Health Care
  • Movers
  • News

Stryker Stock Gains On Q4 Earnings, 2024 Outlook

By Ryan Gustafson
January 30, 6:38 PM
Stryker Corp (NYSE: SYK) shares are trading higher in Tuesday's after-hours session after the company reported better-than-expected fourth-quarter financial results.

SYK

Read More
3 minute read
  • Biotech
  • Cannabis
  • Global
  • Health Care
  • Psychedelics

‘Rainforests Are Nature’s Medicine Cabinets’: Biotech Co. Performs Fresh Research On Traditional Plants For Modern Mental Health Challenges

By Lara Goldstein
January 30, 2:52 PM
Numerous companies in the psychedelics industry are essentially advancing research on compounds that have a history of past…

FLHLF

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News

Life Science Giant Danaher Warns Of Sales Decline In 2024; Says ‘Pandemic Has Transitioned To An Endemic State’

By Vandana Singh
January 30, 12:26 PM
Danaher reported Q4 2023 adjusted EPS of $2.09, exceeding consensus of $1.89. Sales decreased 10% Y/Y to $6.4B. Non-GAAP core revenue declined 11.5%. Guidance for core revenue growth will continue, but not for base business core revenue.

DHR

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Management
  • Movers
  • News

Why Is Hospital Chain HCA Healthcare Stock Trading Higher Today?

By Vandana Singh
January 30, 11:40 AM
HCA Healthcare surpasses Q4 2023 revenue expectations at $17.30B. CEO Sam Hazen highlights strong demand, increased ER visits, and improved financial performance. Mike Marks appointed as new CFO.

HCA

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Why Is Vertex Pharmaceuticals Stock Sliding Today?

By Vandana Singh
January 30, 10:51 AM
Explore Vertex Pharmaceuticals' Phase 3 results for VX-548, a NaV1.8 inhibitor, demonstrating significant pain relief post-surgery.

VRTX

Read More
2 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • News

Pfizer Surprises With Q4 Profit Despite Muted COVID Products Demand, Sticks To 2024 Guidance

By Vandana Singh
January 30, 9:48 AM
Pfizer's Q4 2023 financial report: adjusted EPS beats estimates at $0.10, FY2023 EPS down 72%, Q4 sales decline 41% to $14.25B. CEO's positive outlook and reaffirmed 2024 guidance.

PFE

Posts pagination

Previous 1 … 67 68 69 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service